Welcome to our dedicated page for Galecto news (Ticker: GLTO), a resource for investors and traders seeking the latest updates and insights on Galecto stock.
Galecto, Inc. (NASDAQ: GLTO) is a clinical-stage biopharmaceutical company developing novel therapies for cancer and liver diseases, with a growing focus on hematological malignancies. The GLTO news feed on Stock Titan aggregates company announcements, scientific updates and regulatory disclosures so readers can follow how Galecto’s pipeline and corporate strategy evolve over time.
Recent news emphasizes Galecto’s shift toward blood cancers, highlighted by the acquisition of Damora Therapeutics and the integration of a mutant calreticulin (mutCALR)-driven myeloproliferative neoplasm portfolio. Updates describe progress on DMR-001, an anti-mutCALR monoclonal antibody for essential thrombocythemia and myelofibrosis, and DMR-002, an additional anti-mutCALR antibody. News items also cover GB3226, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia, including preclinical data presentations and plans for first-in-human studies.
Investors and followers of GLTO can use this page to track a range of developments: pipeline milestones such as planned IND submissions, preclinical and early clinical data disclosures, corporate transactions including the Damora acquisition and private placements, and leadership changes like the appointment of new executives with hematology/oncology experience. Financial result releases offer context on Galecto’s operating expenses, research and development priorities and cash runway.
This news archive is useful for anyone monitoring how Galecto executes on its strategy in hematology-oncology and liver disease, from the advancement of DMR-001 and GB3226 to the progress of GB1211 in liver cirrhosis and oncology combinations. Bookmark this GLTO news page to quickly access the latest company press releases and related updates as they are reported.
Galecto, Inc. (NASDAQ: GLTO) reported its Q2 2022 financial results, highlighting significant advancements in its clinical pipeline. The company completed enrollment in the Phase 2b GALACTIC-1 trial for idiopathic pulmonary fibrosis (IPF) and initiated the Phase 2a GALLANT-1 trial for non-small cell lung cancer (NSCLC). Cash and investments stood at approximately $85.9 million, expected to sustain operations into H2 2024. However, the net loss attributable to common stockholders increased to $16.9 million, or $(0.67) per share, compared to $12.3 million, or $(0.49) per share, in the prior year.
Galecto, Inc. (GLTO) has initiated the Phase 2a GALLANT-1 trial, enrolling the first patient to study GB1211, a galectin-3 inhibitor, in combination with Roche's atezolizumab for treating non-small cell lung cancer (NSCLC). This trial seeks to assess the efficacy of GB1211 in enhancing checkpoint inhibition. Pre-clinical studies indicate GB1211's potential to diminish tumor growth and metastasis. Topline data is expected in mid-2023, as Galecto continues its focus on targeted cancer therapies.
Galecto, Inc. (NASDAQ: GLTO) announced its participation at the Jefferies Healthcare Conference, scheduled for June 8-10, 2022, in New York City. The presentation will occur at 3:00 PM ET, and a live webcast will be available on Galecto's investor website. The company is dedicated to developing treatments for cancer and fibrosis, with ongoing clinical trials including GB0139 for idiopathic pulmonary fibrosis and GB2064 for myelofibrosis. For further details, visit their website.
Galecto, Inc. (NASDAQ: GLTO) announced two significant poster presentations for its oral galectin-3 inhibitor, GB1211, at the 2022 ASCO Annual Meeting. The first poster presents findings that GB1211 reverses galectin-3 induced blockade of PD-1/PD-L1 checkpoint inhibitors, potentially enhancing their effectiveness in cancer treatment. The second poster outlines the GALLANT-1 trial, a Phase 2 study examining the combination of GB1211 and atezolizumab in non-small cell lung cancer (NSCLC) patients. The presentations will occur between June 5-6, 2022, and will be accessible on Galecto's website.
On May 2, 2022, Galecto, a clinical stage biotechnology company (NASDAQ: GLTO), announced its participation in two upcoming healthcare conferences. Management will present at the BofA Securities 2022 Healthcare Conference on May 10 at 3:40 pm ET. An additional H.C. Wainwright Global Investment Conference will take place from May 23-26, featuring an on-demand presentation. Galecto is focused on developing treatments for cancer and fibrosis, with several ongoing clinical trials, including for idiopathic pulmonary fibrosis and myelofibrosis.
Galecto, Inc. (NASDAQ: GLTO) reported its financial results for Q1 2022, highlighting significant progress in clinical trials. The company completed enrollment in two Phase 2 trials—GALACTIC-1 for idiopathic pulmonary fibrosis (IPF) and GULLIVER-2 for liver cirrhosis. The total net loss increased to $16.9 million, or $(0.67) per share, from $13.3 million, or $(0.53) per share, year-over-year. As of March 31, 2022, Galecto had approximately $101.8 million in cash and equivalents, expected to fund operations into late 2024.
Galecto, Inc. (NASDAQ: GLTO) announced the completion of patient enrollment for its Phase 2b GALACTIC-1 trial of GB0139, an inhaled galectin-3 inhibitor for idiopathic pulmonary fibrosis (IPF). The trial, involving 141 patients at 100 centers globally, aims to assess the drug's safety and efficacy over 52 weeks. IPF affects around 100,000 people in the U.S., presenting a critical unmet medical need. Results are expected in mid-2023, with GB0139 targeting a significant gap in IPF treatment options.
Galecto, Inc. (NASDAQ: GLTO) has completed enrollment in Parts 2 and 3 of its GULLIVER-2 trial, evaluating GB1211 for liver cirrhosis. Part 1 revealed GB1211 was well-tolerated in patients with moderate hepatic impairment. Part 2 is a 12-week, placebo-controlled study monitoring safety and efficacy in 30 liver cirrhosis patients. Part 3 will assess pharmacokinetics in patients with severe impairment. Results are expected in Q4 2022, as GB1211 shows promise in treating a disease with limited options. Over 100 million worldwide suffer from liver cirrhosis.
Galecto, Inc. (NASDAQ: GLTO) reported its 2021 financial results, highlighting significant pipeline advancements and a robust cash position. The company advanced GB2064 and GB1211 into Phase 2 clinical trials, alongside its ongoing GALACTIC-1 trial for idiopathic pulmonary fibrosis. Galecto has approximately $109.2 million in cash, expected to sustain operations into 2H 2024. Operating expenses increased to $52.2 million, resulting in a net loss of $51.8 million or $(2.05) per share.
Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on fibrosis and cancer treatments, announced participation in two upcoming conferences. The SVB Leerink Healthcare Conference is set for February 16, 2022, at 8:00 am ET, with a live webcast available. The Credit Suisse London Healthcare Conference will take place March 1-4, 2022, featuring one-on-one meetings. Galecto is developing innovative therapies, including a Phase 2b inhaled modulator for idiopathic pulmonary fibrosis.
FAQ
What is the current stock price of Galecto (GLTO)?
What is the market cap of Galecto (GLTO)?
